



## **Notice**

### ***Institutional Investor Magazine:* TOP RANKING for Heliane Canepa and Nobel Biocare**

**In a survey performed by the Institutional Investor Magazine, Heliane Canepa was ranked as the No.1 CEO and Nobel Biocare as the MOST shareholder-friendly company in the European Medical Technologies & Service sector.**

#### **Europe's BEST CEOs of 2006**

The No.1 ranking in the Medical Technologies & Services sector for Heliane Canepa was based on a survey among 800 research analysts and portfolio managers at some 340 money management firms, and 620 sell-side analysts at more than 90 brokerage firms in Europe.

#### **Europe's MOST Shareholder-friendly companies of 2006**

Nobel Biocare was ranked No. 1 in the Medical Technologies & Services sector based on a survey of nearly 1,000 analysts and portfolio managers at 376 firms that manage a combined 3.5 trillion USD in European equities.

#### ***Institutional Investor magazine***

*Institutional Investor magazine is the world's most-read financial monthly publication amongst professional investors and senior corporate financial executives. All of Institutional Investor's rankings are objective, rigorous, and completely independent – there is no editorial influence whatsoever.*

## **NOBEL BIOCARE HOLDING AG**

*For further information please contact:*

Suha Demokan, Head of Investor Relations  
Tel +41 43 211 53 30, +41 79 430 81 46  
e-mail [suha.demokan@nobelbiocare.com](mailto:suha.demokan@nobelbiocare.com)

Gunilla Ekholtz, Investor Relations Officer  
Tel +46 31 81 88 36, +46 708 81 88 36  
e-mail [gunilla.ekholtz@nobelbiocare.com](mailto:gunilla.ekholtz@nobelbiocare.com)

Nobel Biocare is a medical devices group and the world leader in innovative esthetic dental solutions with its brands Brånemark System®, NobelSpeedy™, NobelReplace™, NobelPerfect®, NobelDirect®, Replace® Select, (dental implants) and Procera® (individualized dental prosthetics). Nobel Biocare is a one-stop shop for restorative esthetic dentistry, offering a wide range of innovative Crown & Bridge & Implant products, as well as training and education and clinically documented treatment concepts. Nobel Biocare has more than 1,800 employees and recorded revenue of EUR 485 million in 2005. The company is domiciled in Zurich, Switzerland with headquarters in Zurich and in Gothenburg, Sweden. Production takes place at four production sites located in Sweden and the USA. Nobel Biocare has direct sales organizations in 33 countries. The shares of the parent company Nobel Biocare Holding AG are listed on the SWX Swiss Exchange and on the Stockholm Stock Exchange, Sweden.